|
CA2752389A1
|
|
Use of ingenols in the treatment of aged skin
|
|
CA2685473A1
|
|
Treatment of virally induced lesions
|
|
WO2007068963A2
|
|
Therapeutic compositions comprising ingenol-3-angelate
|
|
BRPI0618926A2
|
|
use of an ingenol compound or a pharmaceutically acceptable salt thereof
|
|
AU2006313017A1
|
|
Use of angeloyl-substituted ingenanes in combination with other agents to treat cancer
|
|
KR20080080539A
|
|
Use of angeloyl-substituted ingenanes in combination with other agents to treat cancer
|
|
AU2006201661A1
|
|
A method of diagnosis and treatment
|
|
CA2541903A1
|
|
A method of diagnosis and treatment
|
|
EP1838330A1
|
|
Treatment of solid cancers
|
|
AU2002953257A0
|
|
Generation of biologically active compounds
|
|
CA2418784A1
|
|
Use of compounds derived from the genus euphorbia for the treatment of carcinoma of the bladder
|
|
AU7949301A
|
|
Treatment of prostate cancer
|
|
AU6366101A
|
|
Therapeutic agents - I
|
|
AU6366201A
|
|
Therapeutic agents - II
|
|
CA2411642A1
|
|
Use of ingenanes for the activation of latent virus infection
|
|
AU7373201A
|
|
Therapeutic agents - III
|
|
AU4811601A
|
|
Anti-cancer compounds-I
|
|
AU4811701A
|
|
Anti-cancer compounds-III
|
|
AU4811801A
|
|
Anti-cancer compounds-II
|
|
EP1221951A1
|
|
Treatment of pancreatic disease
|
